Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Schering-Plough Clarifies Golimumab Rights | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Schering-Plough Clarifies Golimumab Rights

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough received clarification regarding the expiration date for its rights to market golimumab worldwide, excluding the U.S., Japan and certain other Asian markets. In August 2005, Schering-Plough and Centocor stated that they were working together to move forward with their collaboration on golimumab and were taking steps to resolve the difference of opinion as to the expiration date.

Schering-Plough’s rights to market golimumab will extend to 15 years after the first commercial sale in its territories. The company plans to launch golimumab in 2009 or 2010.

Developed by Centocor and Schering-Plough, golimumab is a fully-human monoclonal antibody being developed as a treatment for certain immune-mediated inflammatory diseases. Golimumab is currently being investigated in Phase III trials for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters